Other
Sintilimab
0
Pipeline Programs↗
10
Active Trials↗
1
Companies Involved↗
Sintilimab is an early-stage landscape with 0 programs across 1 company. The most active players are Innovent Biologics (Suzhou) Co. Ltd..
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
No pipeline programs currently tracked for this disease.
Analysis
Trial Status
21
clinical trials
Recruiting7 · 33%
Completed6 · 29%
Unknown status5 · 24%
Not yet recruiting3 · 14%
Clinical Trials
Trial Activity
21 trials
SCRT-NALIRIXELOX+Sintilimab as TNT for High-Risk LARC
Recruiting·UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology·N/A·NCT07474103·49 enrolled
Lenvatinib+Sintilimab+TACE vs. Lenvatinib+TACE for Advanced HCC
Recruiting·SSecond Affiliated Hospital of Guangzhou Medical University·Phase 3·NCT05608200·427 enrolled
Sintilimab Plus Anlotinib as Second or Further-line Therapy for ES-SCLC Who Have Progressed After Anti-PD-1/L1 Therapy
Not yet recruiting·FFirst Affiliated Hospital of Wannan Medical College·Phase 2·NCT07022301·25 enrolled
TACE Combined With Lenvatinib and Sintilimab for Advanced HCC
Completed·SSecond Affiliated Hospital of Guangzhou Medical University·Phase 2·NCT04599790·30 enrolled
Donafenib Plus Sintilimab for Advanced HCC
Completed·SSecond Affiliated Hospital of Guangzhou Medical University·Phase 2·NCT05162352·30 enrolled
Page 1 of 2
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)